Geneva Capital Management LLC Sells 345 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Geneva Capital Management LLC cut its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 8.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,963 shares of the medical equipment provider’s stock after selling 345 shares during the period. Geneva Capital Management LLC’s holdings in Intuitive Surgical were worth $1,947,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Creekmur Asset Management LLC grew its position in shares of Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 42 shares in the last quarter. Ridgewood Investments LLC bought a new stake in shares of Intuitive Surgical during the second quarter valued at about $26,000. Delos Wealth Advisors LLC lifted its holdings in shares of Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 57 shares in the last quarter. Godsey & Gibb Inc. boosted its position in shares of Intuitive Surgical by 140.0% in the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 35 shares during the period. Finally, LRI Investments LLC purchased a new position in Intuitive Surgical during the first quarter valued at approximately $30,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Amy L. Ladd sold 450 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the transaction, the director now directly owns 821 shares of the company’s stock, valued at approximately $402,519.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Amy L. Ladd sold 450 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the transaction, the director now owns 821 shares in the company, valued at $402,519.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jamie Samath sold 269 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $539.89, for a total value of $145,230.41. Following the completion of the sale, the insider now owns 8,757 shares of the company’s stock, valued at approximately $4,727,816.73. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 91,178 shares of company stock valued at $45,897,071 in the last quarter. Insiders own 0.80% of the company’s stock.

Intuitive Surgical Trading Up 0.2 %

NASDAQ ISRG opened at $537.07 on Wednesday. The firm has a market cap of $191.29 billion, a PE ratio of 86.35, a price-to-earnings-growth ratio of 5.27 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $281.12 and a 1-year high of $542.59. The stock has a 50-day moving average of $494.78 and a 200-day moving average of $453.94.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The firm had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ISRG. Mizuho increased their target price on shares of Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday, October 17th. Piper Sandler reiterated an “overweight” rating and issued a $538.00 price objective (up previously from $495.00) on shares of Intuitive Surgical in a research report on Friday, October 18th. Stifel Nicolaus boosted their target price on Intuitive Surgical from $475.00 to $525.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. The Goldman Sachs Group set a $604.00 price target on Intuitive Surgical in a report on Friday, October 18th. Finally, Truist Financial upped their price objective on shares of Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average target price of $513.74.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.